The impact of alcohol pharmacotherapies on public health in Australia is limited by low prescribing rates

Paul S. Haber; Kirsten C. Morley

doi:10.17061/phrp2641643

The impact of alcohol pharmacotherapies on public health in Australia is limited by low prescribing rates

Paul S. Haber^*, Kirsten C. Morley

^*Corresponding author for this work

Research output: Contribution to journal › Comment/opinion › peer-review

8 Citations (Scopus)

21 Downloads (Pure)

Abstract

Alcohol use disorders are among the most common and disabling problems in Australia. A number of pharmacotherapies available in Australia have been shown to be effective and are subsidised through the Australian Government's Pharmaceutical Benefits Scheme. The uptake of these medicines is poor, and the majority of those who start treatment do not complete the recommended course. Use of these medicines is significantly lower in regions that are disadvantaged or remote, and in patients who are younger. Taken together, these factors limit the potential benefit to population health from treatment of alcohol use disorders. Barriers to treatment have been identified at the level of the patient, the provider, the medicine and the healthcare system. An integrated strategy may be required to overcome these barriers.

Original language	English
Article number	e2641643
Pages (from-to)	1-4
Number of pages	4
Journal	Public Health Research and Practice
Volume	26
Issue number	4
DOIs	https://doi.org/10.17061/phrp2641643
Publication status	Published - 30 Sept 2016
Externally published	Yes

Bibliographical note

Copyright the Author(s) 2016. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Access to Document

10.17061/phrp2641643

Publisher version (open access)Final published version, 147 KBLicence: CC BY-NC-SA

Cite this

@article{1494106fcb6e4e5598fda3b5bc10cd64,

title = "The impact of alcohol pharmacotherapies on public health in Australia is limited by low prescribing rates",

abstract = "Alcohol use disorders are among the most common and disabling problems in Australia. A number of pharmacotherapies available in Australia have been shown to be effective and are subsidised through the Australian Government's Pharmaceutical Benefits Scheme. The uptake of these medicines is poor, and the majority of those who start treatment do not complete the recommended course. Use of these medicines is significantly lower in regions that are disadvantaged or remote, and in patients who are younger. Taken together, these factors limit the potential benefit to population health from treatment of alcohol use disorders. Barriers to treatment have been identified at the level of the patient, the provider, the medicine and the healthcare system. An integrated strategy may be required to overcome these barriers.",

author = "Haber, \{Paul S.\} and Morley, \{Kirsten C.\}",

note = "Copyright the Author(s) 2016. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2016",

month = sep,

day = "30",

doi = "10.17061/phrp2641643",

language = "English",

volume = "26",

pages = "1--4",

journal = "Public Health Research and Practice",

issn = "1034-7674",

publisher = "CSIRO Publishing",

number = "4",

}

TY - JOUR

T1 - The impact of alcohol pharmacotherapies on public health in Australia is limited by low prescribing rates

AU - Haber, Paul S.

AU - Morley, Kirsten C.

N1 - Copyright the Author(s) 2016. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2016/9/30

Y1 - 2016/9/30

N2 - Alcohol use disorders are among the most common and disabling problems in Australia. A number of pharmacotherapies available in Australia have been shown to be effective and are subsidised through the Australian Government's Pharmaceutical Benefits Scheme. The uptake of these medicines is poor, and the majority of those who start treatment do not complete the recommended course. Use of these medicines is significantly lower in regions that are disadvantaged or remote, and in patients who are younger. Taken together, these factors limit the potential benefit to population health from treatment of alcohol use disorders. Barriers to treatment have been identified at the level of the patient, the provider, the medicine and the healthcare system. An integrated strategy may be required to overcome these barriers.

AB - Alcohol use disorders are among the most common and disabling problems in Australia. A number of pharmacotherapies available in Australia have been shown to be effective and are subsidised through the Australian Government's Pharmaceutical Benefits Scheme. The uptake of these medicines is poor, and the majority of those who start treatment do not complete the recommended course. Use of these medicines is significantly lower in regions that are disadvantaged or remote, and in patients who are younger. Taken together, these factors limit the potential benefit to population health from treatment of alcohol use disorders. Barriers to treatment have been identified at the level of the patient, the provider, the medicine and the healthcare system. An integrated strategy may be required to overcome these barriers.

UR - https://www.scopus.com/pages/publications/84996606803

U2 - 10.17061/phrp2641643

DO - 10.17061/phrp2641643

M3 - Comment/opinion

C2 - 27714386

AN - SCOPUS:84996606803

SN - 1034-7674

VL - 26

SP - 1

EP - 4

JO - Public Health Research and Practice

JF - Public Health Research and Practice

IS - 4

M1 - e2641643

ER -

The impact of alcohol pharmacotherapies on public health in Australia is limited by low prescribing rates

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this